Understanding why patients with blood cancers may not take their oral cancer medications as prescribed
Identifying Multi-Level Predictors and Outcomes of Oral Anticancer Medication Adherence Initiation and Persistence among Patients with Hematologic Malignancies
This study is looking at what helps or hinders patients with blood cancers, like multiple myeloma and chronic lymphocytic leukemia, from starting and sticking to their oral cancer medications, so we can find better ways to support them and improve their health and quality of life.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10942408 on NIH RePORTER |
What this research studies
This research investigates the factors that influence whether patients with hematologic malignancies, such as multiple myeloma and chronic lymphocytic leukemia, start and continue taking their prescribed oral anticancer medications. By examining various influences on medication adherence, including personal, social, and systemic factors, the study aims to identify why some patients struggle with adherence. The research will analyze patient data to categorize adherence patterns and understand the impact of these patterns on health outcomes, particularly focusing on racial and ethnic differences. The goal is to develop strategies to improve adherence and ultimately enhance patient quality of life.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with hematologic malignancies who are prescribed oral anticancer medications.
Not a fit: Patients who are not prescribed oral anticancer medications or those with non-hematologic cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for ensuring patients take their oral cancer medications as prescribed, potentially enhancing treatment outcomes.
How similar studies have performed: Previous research has shown that addressing medication adherence in chronic conditions can lead to significant improvements in patient outcomes, suggesting that this approach may also be effective for hematologic malignancies.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Belcher, Sarah M. — University of Pittsburgh at Pittsburgh
- Study coordinator: Belcher, Sarah M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.